Biomerica (BMRA) and Its Competitors Head-To-Head Analysis

Biomerica (NASDAQ:BMRA – Get Free Report) is one of 511 publicly-traded companies in the “Healthcare Equipment & Supplies” industry, but how does it weigh in compared to its rivals? We will compare Biomerica to similar companies based on the strength of its analyst recommendations, risk, earnings, profitability, institutional ownership, valuation and dividends.

Valuation & Earnings

This table compares Biomerica and its rivals gross revenue, earnings per share and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Biomerica $4.34 million -$3.78 million -0.80
Biomerica Competitors $1.90 billion $137.78 million 5.72

Biomerica’s rivals have higher revenue and earnings than Biomerica. Biomerica is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Profitability

This table compares Biomerica and its rivals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Biomerica -115.50% -142.81% -77.83%
Biomerica Competitors -300.70% -179.63% -22.71%

Institutional and Insider Ownership

22.3% of Biomerica shares are owned by institutional investors. Comparatively, 40.6% of shares of all “Healthcare Equipment & Supplies” companies are owned by institutional investors. 12.3% of Biomerica shares are owned by insiders. Comparatively, 15.0% of shares of all “Healthcare Equipment & Supplies” companies are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Volatility and Risk

Biomerica has a beta of 0.4, indicating that its share price is 60% less volatile than the S&P 500. Comparatively, Biomerica’s rivals have a beta of 2.58, indicating that their average share price is 158% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Biomerica and its rivals, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Biomerica 1 0 0 0 1.00
Biomerica Competitors 4314 10602 18396 838 2.46

Biomerica presently has a consensus target price of $9.00, indicating a potential upside of 581.82%. As a group, “Healthcare Equipment & Supplies” companies have a potential upside of 22.28%. Given Biomerica’s higher possible upside, equities analysts plainly believe Biomerica is more favorable than its rivals.

Summary

Biomerica rivals beat Biomerica on 10 of the 13 factors compared.

Biomerica Company Profile

(Get Free Report)

Biomerica, Inc. is a medical diagnostic company that develops, manufactures and markets in vitro diagnostic products. Its tests are designed to help detect and assess a range of health conditions, with a focus on gastrointestinal disorders, food sensitivities and related areas. The company’s offerings include laboratory-based and point-of-care tests, including its inFoods IBS blood test, which is intended to help guide dietary management for people with irritable bowel syndrome. Biomerica also sells diagnostic products for other applications, including infectious and inflammatory conditions.

Receive News & Ratings for Biomerica Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biomerica and related companies with MarketBeat.com's FREE daily email newsletter.